News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen Class of 2024
Insights
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Jobs
Career Advice
Companies
Hotbeds
More
Employer Resources
Best Places to Work
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen Class of 2024
Insights
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Jobs
Career Advice
Companies
Hotbeds
More
Employer Resources
Best Places to Work
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Search Query
Submit Search
Search Results
Submit
Looking for jobs?
Search jobs
Close
163,955 Results
Type
Article (6600)
Company Profile (124)
Press Release (157231)
Section
Business (53704)
Career Advice (338)
Deals (9744)
Drug Delivery (27)
Drug Development (31881)
Employer Resources (66)
FDA (2706)
Job Trends (4120)
News (96216)
Policy (6726)
Tag
Academia (253)
Africa (164)
Alliances (12139)
Alzheimer's disease (331)
Approvals (2687)
Artificial intelligence (29)
Asia (13087)
Australia (1407)
Bankruptcy (60)
Best Places to Work (3111)
Biotechnology (82)
C2C Services and Suppliers (2697)
California (746)
Canada (267)
Cancer (172)
Career advice (289)
Cell therapy (42)
China (90)
Clinical research (26072)
Collaboration (46)
Colorado (23)
Compensation (55)
Connecticut (27)
COVID-19 (628)
Data (148)
Diabetes (25)
Diagnostics (568)
Earnings (22149)
Employer resources (57)
Europe (23712)
Events (32370)
Executive appointments (73)
FDA (2770)
Florida (73)
Funding (41)
GLP-1 (188)
Government (691)
Healthcare (2250)
Hotbed/Location (119184)
Illinois (33)
Indiana (41)
Infectious disease (635)
Inflammatory bowel disease (35)
Interviews (54)
IPO (5685)
Job creations (1019)
Job search strategy (253)
Kansas (44)
Layoffs (112)
Legal (894)
Liver cancer (19)
Lung cancer (39)
Management (20)
Manufacturing (39)
Maryland (111)
Massachusetts (680)
Medical device (439)
Medtech (440)
Mergers & acquisitions (4084)
Metabolic disorders (80)
Michigan (25)
Minnesota (34)
Neuroscience (385)
New Jersey (287)
New York (322)
NextGen Class of 2024 (967)
Non-profit (233)
North Carolina (235)
Northern California (336)
Now hiring (22)
Obesity (42)
Ohio (40)
Opinion (68)
Patents (25)
Pennsylvania (173)
People (16694)
Pharmaceutical (40)
Phase I (7856)
Phase II (12010)
Phase III (8792)
Pipeline (56)
Podcasts (31)
Policy (31)
Postmarket research (511)
Preclinical (2925)
Radiopharmaceuticals (103)
Rare diseases (37)
Real estate (1194)
Recruiting (27)
Regulatory (5402)
Research institute (280)
Resumes & cover letters (40)
South America (208)
Southern California (317)
Startups (955)
Texas (79)
United States (3099)
Vaccines (98)
Washington State (63)
Weight loss (28)
Date
Today (42)
Last 7 days (191)
Last 30 days (895)
Last 365 days (13396)
2024 (9539)
2023 (14344)
2022 (16206)
2021 (17853)
2020 (15242)
2019 (10008)
2018 (7160)
2017 (8985)
2016 (7360)
2015 (9317)
2014 (7062)
2013 (5085)
2012 (4915)
2011 (4844)
2010 (4810)
163,955 Results for "aytu biopharma".
Filters
Sort By
Relevance
Relevance
Newest
Oldest
Aytu BioPharma Announces Paydown and Refinancing of Term Loan on More Favorable Terms
Aytu BioPharma, Inc. today announced the successful refinancing of its existing term loan and extension of its revolving credit facility on more favorable terms to the Company.
June 18, 2024
·
6 min read
Business
Aytu BioPharma to Report Third Quarter Fiscal 2024 Financial and Operational Results on May 15, 2024
Aytu BioPharma, Inc. (the “Company” or “Aytu”) (NASDAQ:AYTU), a pharmaceutical company focused on commercializing novel therapeutics, will report its financial and operational results for its third quarter of fiscal 2024 for the period ended March 31, 2024, after the market close on Wednesday, May 15, 2024.
May 8, 2024
·
1 min read
BioMidwest
Aytu BioPharma to Participate in the Lytham Partners Spring 2024 Investor Conference on May 30, 2024
Aytu BioPharma, Inc. announced that Josh Disbrow, CEO, will participate in a webcasted fireside chat and host one-on-one meetings with investors at the Lytham Partners Spring 2024 Investor Conference, taking place virtually on Thursday, May 30, 2024.
May 23, 2024
·
1 min read
Aytu BioPharma to Present at the Emerging Growth Conference on April 4, 2024
Aytu BioPharma, Inc. today announced that its CEO, Josh Disbrow, will be participating in the Emerging Growth Conference.
April 3, 2024
·
1 min read
Business
Aytu BioPharma to Report Fiscal 2024 Full Year and Fourth Quarter Operational and Financial Results on September 26, 2024
September 19, 2024
·
2 min read
Business
Aytu BioPharma Reports Record ADHD Revenue and Operating Income During Fiscal 2024 Second Quarter
Aytu BioPharma, Inc. (the “Company” or “Aytu”) (NASDAQ:AYTU), a pharmaceutical company focused on commercializing novel therapeutics, today announced financial and operational results for the fiscal 2024 second quarter.
February 14, 2024
·
14 min read
Business
Aytu BioPharma to Report Second Quarter Fiscal 2024 Financial and Operational Results on February 14, 2024
Aytu BioPharma, Inc. (the “Company” or “Aytu”) (NASDAQ:AYTU), a pharmaceutical company focused on commercializing novel therapeutics, will report its financial and operational results for its second quarter of fiscal 2024 for the period ended December 31, 2023, after the market close on Wednesday, February 14, 2024.
February 7, 2024
·
2 min read
Business
Aytu BioPharma to Participate in the Sidoti Micro-Cap Virtual Conference on August 14-15, 2024
August 8, 2024
·
1 min read
Press Releases
Aytu BioPharma Announces Sale of Consumer Health Business Following Wind Down of Consumer Health Operations
August 6, 2024
·
4 min read
Business
Aytu BioPharma Reports Fiscal 2024 First Quarter Financial Results
Aytu BioPharma, Inc. (the Company or “Aytu”) (NASDAQ:AYTU), a pharmaceutical company focused on commercializing novel therapeutics, today announced financial and operational results for the first quarter of fiscal 2024 ended September 30, 2023.
November 14, 2023
·
15 min read
1 of 16,396
Next
